Aeluma (ALMU) Q4 2026 Earnings Call Transcript

Aeluma reported fiscal 2026 revenue of $4.5 million, down from $4.7 million, while GAAP net loss widened to $9.2 million ($0.52 per share) from $3.0 million as it increased hiring and commercialization spending. The company ended the year with $56 million of cash after raising $20.1 million through an ATM equity issuance, and expects $10 million-$12 million of fiscal 2027 CapEx for MOCVD reactors and validation equipment. Management is shifting from government R&D toward AI-datacom photonics, with $2.3 million of booked fiscal 2027 government revenue, potential additional $2 million opportunities, commercial NRE negotiations, and a non-final CHIPS funding LOI of up to $30 million.

Analysis

ALMU is being valued as a scarce-materials workaround before it has demonstrated a qualified commercial device, customer design win, or production yield. The relevant valuation bridge is therefore not AI datacenter capex but conversion of NRE engagements into recurring component revenue; NRE can validate demand but is low-margin, non-repeatable, and may not establish pricing power. The company’s limited revenue visibility means even a modest slip in qualification or customer-funded program timing can force a sharp reset in FY27 expectations.

The proposed CHIPS transaction is a double-edged catalyst: capital would extend runway and de-risk equipment deployment, but equity accounting implies dilution rather than operating revenue, while definitive terms, milestones, and timing remain unresolved. Combined with the remaining ATM capacity, ALMU has a structurally open equity-supply overhang precisely while cash burn, headcount, and equipment spending ramp. AIXA benefits more immediately from reactor orders, whereas ALMU assumes the execution risk of turning those tools into reproducible, customer-qualified output.

Near term, the stock can trade on a signed commercial NRE or final CHIPS agreement. Over 6-18 months, the key question is whether large-wafer processing actually produces a cost/yield advantage after packaging and reliability qualification; incumbents such as LITE, AAOI, COHR and Fabrinet-linked supply chains already have customer qualification and volume-manufacturing advantages. Consensus appears to underweight the possibility that indium-phosphide tightness is alleviated by capacity additions before ALMU’s products reach volume, reducing the urgency premium.

Falsify the cautious view with a named-tier-one NRE/design win that includes production volumes, binding economics, and delivery milestones, plus a commercial revenue guide sufficient to cover the enlarged operating base. Conversely, failure to close CHIPS terms, further ATM issuance below the recent issuance price, or quarterly cash burn remaining near the current run-rate without commercial bookings would make the equity increasingly financing-driven.

Key Decisions for Investors

• Avoid initiating a core long in ALMU ahead of definitive CHIPS terms and at least one disclosed commercial NRE with scope, timing, and conversion path; use a signed agreement as the entry trigger rather than management pipeline language.
• For event-driven exposure, maintain only a small long ALMU position through the next 1-3 months, sized for binary contract/funding outcomes; take profits on a funding-driven rally unless terms exclude material dilution and establish clear milestone funding.
• Prefer long AIXA over ALMU for a 6-12 month AI-photonics manufacturing theme: reactor demand is monetized at equipment sale, while ALMU must still clear process qualification, yield, packaging, and customer adoption. Reassess if AIXA order commentary weakens or ALMU discloses binding volume commitments.
• Set a dilution alert on ALMU: additional ATM usage before commercial NRE disclosure, particularly below the prior issuance price, is a thesis-negative signal and supports reducing exposure.
• Monitor quarterly booked commercial revenue, cash burn, capex installation/qualification milestones, and any disclosed yield or reliability data. Do not underwrite recurring datacom revenue until these indicators demonstrate progression beyond development activity.